Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy

BRAF is the most prevalent oncogene and an important therapeutic target in melanoma. In some cancers BRAF is activated by rearrangements that fuse its kinase domain to 5’ partner genes. We examined 848 comparative genomic hybridization profiles of melanocytic tumors and found copy number transitions...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Botton, Thomas, Yeh, Iwei, Nelson, Tyrrell, Vemula, Swapna S., Sparatta, Alyssa, Garrido, Maria C., Allegra, Maryline, Rocchi, Stephane, Bahadoran, Philippe, McCalmont, Timothy H., LeBoit, Philip E., Burton, Elizabeth A., Bollag, Gideon, Ballotti, Robert, Bastian, Boris C.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2013
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3808507/
https://ncbi.nlm.nih.gov/pubmed/23890088
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/pcmr.12148
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia